stockrowAurinia Pharmaceuticals Inc
AUPH Healthcare Biotechnology
Aurinia Pharmaceuticals Inc’s revenue for fiscal 2025 (year ended December 2025) was $283.1 million, up 20.4% from fiscal 2024.
- Revenue
- +13.9%
- EPS
- 0.00%
- Free cash flow
- +4.41%
- Total debt
- −30.0%
Quarter to September 2026, against a year earlier
Follow AUPH
Alert me
Aurinia Pharmaceuticals Inc (AUPH) Revenue growth
Aurinia Pharmaceuticals Inc's revenue growth over the twelve months to 30 September 2026 was 21.0%, up 0.7 percentage points from fiscal 2025 (20.4%). Over the past ten years it has ranged from −31.3% (fiscal 2019) to 15,660.4% (fiscal 2020); the current reading is higher than 55% of that period. That is above the Biotechnology industry median of 6.26% and above the Healthcare sector median of 7.80%.
Revenue growth, annual
Embed this chart
Annual newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| FY2025 | 20.4% | (13.59) |
| FY2024 | 34.0% | 3.02 |
| FY2023 | 31.0% | (162.94) |
| FY2022 | 193.9% | 202.89 |
| FY2021 | −9.00% | (15,669.38) |
| FY2020 | 15,660.4% | 15,691.70 |
| FY2019 | −31.3% | (42.09) |
| FY2018 | 10.8% | (130.85) |
| FY2017 | 141.6% | 168.00 |
| FY2016 | −26.4% | (10.91) |
Quarterly newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| Sep 2026 | 13.9% | (4.94) |
| Jun 2026 | 18.9% | (5.53) |
| Mar 2026 | 24.4% | (4.41) |
| Dec 2025 | 28.8% | 20.40 |
| 43 more quarters | Free account |
Against its own ten years
Revenue growth against peers
| Company | Revenue growth |
|---|---|
| BHVN Biohaven Ltd. compare | 425.2% |
| PVLA Palvella Therapeutics, Inc. compare | 146.7% |
| VCEL Vericel Corporation compare | 25.3% |
| AUPH Aurinia Pharmaceuticals Inc | 21.0% |
| IMNM Immunome, Inc. compare | 16.7% |
| ADMA ADMA Biologics Inc compare | 6.26% |
| LKFT Lakefront Biotherapeutics - Sponsored ADR compare | −52.2% |
| CLDX Celldex Therapeutics, Inc. compare | −88.3% |
| VERA Vera Therapeutics, Inc. compare | — |
| Biotechnology industry median | 6.26% |
| Healthcare sector median | 7.80% |
| Market median | 7.58% |
What Revenue growth is
Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.
(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|
More on AUPH
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement